NEUROLOGIST, an esteemed journal published by Lippincott Williams & Wilkins, serves as a vital resource in the fields of Neurology and Medicine. With an ISSN of 1074-7931 and an E-ISSN of 2331-2637, this journal has been dedicated to advancing the understanding of neurological disorders since its inception in 1996, with continual contributions through 2024. Achieving a respectable Q3 rank in both Medicine (miscellaneous) and Neurology (clinical), it provides an essential platform for disseminating innovative research and clinical studies. Although it is not an open-access publication, NEUROLOGIST promotes a rich exchange of ideas and findings for researchers, healthcare professionals, and students alike, helping to bridge the gaps in neurological research and practice. The journal is recognized for its commitment to enhancing clinical practice and research methodology, making it a valuable asset for anyone engaged in the dynamic field of neurology.

Neurodegenerative Disease Management is a distinguished journal published by FUTURE MEDICINE LTD, focusing on the pivotal issues surrounding the management of neurodegenerative diseases. Since its inception in 2014, this journal has emerged as a significant resource within the fields of medicine and neurology, currently holding a respected position with a Q2 category ranking in Medicine (miscellaneous) and Q3 in Neurology (clinical) for 2023. With an ISSN of 1758-2024 and E-ISSN 1758-2032, the journal provides a platform for the dissemination of innovative research, clinical practices, and advancements in treatment strategies for conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. The journal is particularly committed to enhancing knowledge sharing among researchers, health professionals, and students, contributing to the collective effort in combatting neurodegenerative diseases. Though not open access, its articles are meticulously curated to ensure high-quality, impactful contributions to the field, making it an essential reference for those engaged in neurology and related disciplines.

NEUROBIOLOGY OF DISEASE is a premier journal dedicated to advancing the understanding of neurological disorders and the underlying biological processes, published by Academic Press Inc, Elsevier Science. With an impressive impact factor indicative of its significance—ranked in the Q1 quartile in Neurology for 2023 and occupying the 14th rank out of 192 journals in the field of Neuroscience and Neurology—this journal serves as a critical resource for researchers, clinicians, and students alike. The journal has a rich history since its inception in 1994, continuously evolving its scope to encompass groundbreaking research and insights into neurobiological mechanisms and disease pathology. Though it currently does not provide Open Access options, NEUROBIOLOGY OF DISEASE remains a vital vessel for disseminating knowledge that significantly contributes to the field of neurology, fostering an understanding that can lead to innovative therapeutic strategies.

FOLIA NEUROPATHOLOGICA is a distinguished Open Access journal specializing in the fields of Neurology and Pathology, published by the reputable TERMEDIA PUBLISHING HOUSE LTD. With an ISSN of 1641-4640 and E-ISSN 1509-572X, this journal has been a vital resource for the dissemination of high-quality research since its inception in 1994. Covering a broad spectrum of topics within neuropathology, the journal emphasizes clinical findings and forensic implications, making it an essential platform for healthcare professionals, researchers, and students alike. With impressive impact factors positioning it in the Q3 category for both Neurology (clinical) and Pathology and Forensic Medicine, FOLIA NEUROPATHOLOGICA occupies a significant place among its peers, ranked within the 36th to 46th percentiles on Scopus. Scholars can benefit from the Open Access model implemented since 2005, ensuring wide accessibility and distribution of critical research outputs aimed at advancing both clinical practices and academic knowledge. Based in Poland, at KLEEBERGA 2, POZNAN 61-615, this journal continues to shape the discourse in neuropathology and related fields.

Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

Alzheimers & Dementia is a premier journal published by WILEY that focuses on the latest advancements in understanding, diagnosing, and treating Alzheimer's disease and other dementias. With an ISSN of 1552-5260 and an E-ISSN of 1552-5279, this influential journal boasts a commendable impact factor and ranks in the Q1 category across several disciplines, including *Cellular and Molecular Neuroscience*, *Geriatrics and Gerontology*, and *Neurology (Clinical)*. By publishing cutting-edge research, systematic reviews, and innovative clinical trials, Alzheimers & Dementia aims to bridge the gap between basic neuroscience and clinical practice, offering valuable insights into the etiology, epidemiology, and management of dementia-related disorders. The journal is hosted in the United States and operates under a balanced access model, providing essential resources for researchers, healthcare professionals, and students dedicated to tackling the challenges posed by these neurodegenerative diseases. Available online, it plays a pivotal role in shaping current and future research directions in the vibrant field of dementia studies.

Alzheimer's Research & Therapy is a leading peer-reviewed journal published by BMC, dedicated to advancing our understanding of Alzheimer's disease and other neurodegenerative disorders. As an Open Access journal since 2009, it ensures that vital research findings are freely accessible to the global community, facilitating collaboration and innovation in the field. The journal's commitment to quality is evident in its impressive impact factor and its prestigious ranking in the Q1 quartile across multiple categories including Cognitive Neuroscience and Neurology. With a Scopus rank placing it in the top tier of both Neuroscience and Neurology disciplines, Alzheimer's Research & Therapy serves as a crucial platform for researchers, clinicians, and students who seek to contribute to the fight against Alzheimer's and related disorders. The journal covers a wide range of topics and actively encourages submissions that explore therapeutic strategies and innovative research methodologies, enriching the scientific dialogue in this vital area of health.

NEUROLOGICAL SCIENCES, published by SPRINGER-VERLAG ITALIA SRL, is a premier journal that has been a cornerstone in the field of neurology and related disciplines since its inception in 1996. With an impressive Q1 ranking in Dermatology and Q2 rankings in Neuroloy (clinical) as well as Psychiatry and Mental Health, this journal consistently delivers high-quality peer-reviewed research that informs and shapes clinical practice. The journal boasts a significant presence on Scopus, positioned in the 89th percentile for Dermatology, 73rd for Psychiatry and Mental Health, and 72nd for Neurology (clinical), reflecting its influential contributions to medical knowledge. Open Access options are available, ensuring that this valuable research is accessible to a wider audience committed to advancing their understanding of neurological sciences. As it converges into future years (2024 and beyond), NEUROLOGICAL SCIENCES aims to continue foster collaboration and innovation amongst researchers, professionals, and students within the neurology and mental health domains, making it an indispensable resource for those dedicated to improving patient outcomes and advancing scholarly dialogue.

AIMS Neuroscience is an esteemed open-access journal published by the American Institute of Mathematical Sciences (AIMS), dedicated to advancing the field of neuroscience since its inception in 2014. With a robust ISSN of 2373-8006 and an E-ISSN of 2373-7972, this journal aims to provide a platform for innovative research and scholarly discourse that spans the diverse and dynamic landscape of the neuroscience discipline. As of 2023, it holds a respectable Q3 category ranking in the miscellaneous neuroscience field and ranks #65 out of 113 in general neuroscience according to Scopus, positioning it in the 42nd percentile for impact. AIMS Neuroscience encompasses a broad scope of topics, from neurobiology and cognitive neuroscience to computational models and neuroengineering, making it a vital resource for researchers, professionals, and students alike. The journal's commitment to open access ensures that cutting-edge research is freely available, fostering collaboration and knowledge sharing within the global neuroscience community.

NeuroImage-Clinical is a premier open access journal published by Elsevier Science Ltd, dedicated to advancing the field of clinical neuroimaging and its applications in a variety of neurological disorders. With an ISSN of 2213-1582, this journal has established itself as a leading source of innovative research since its inception in 2012, now continuing through 2024. Recognized for its high impact, it occupies the top quartile (Q1) in prestigious categories such as Cognitive Neuroscience, Neurology, and Radiology, affirming its relevance in clinical and research settings. Its Scopus rankings further exemplify its significant contribution to the disciplines of Radiology and Neurology, consistently placing it among the top tiers of journals in these fields. This journal not only provides critical insights for researchers and professionals but also serves as a valuable resource for students, fostering an understanding of the complexities in neuroimaging techniques and their implications for patient care. With open access options ensuring broad dissemination of knowledge, NeuroImage-Clinical plays a pivotal role in enhancing collaboration and innovation within the global neuroscience community.